Thunyatorn Wuttiputhanun

Thunyatorn Wuttiputhanun

Auto-generated profile, based on publicly available information

Thunyatorn Wuttiputhanun

Division of Nephrology Department of Medicine Faculty of Medicine Chulalongkorn University Bangkok Thailand

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Kidney360
Verified
Journal Article
Open access
PAPeemai Amornkanjanawat
Peemai Amornkanjanawat
SKStephen Kerr
Stephen Kerr
TWThunyatorn Wuttiputhanun
Thunyatorn Wuttiputhanun
NTNatavudh Townamchai
Natavudh Townamchai
ALAsada Leelahavanichkul
Asada Leelahavanichkul
SUSuwasin Udomkarnjananun
Suwasin Udomkarnjananun
Key Points: Kidney allograft rejection is an independent risk factor for post-transplant cardiovascular events (CVEs), regardless of kidney allograft function. Time-updated post-transplant variables were more associated with post-kidney transplantation CVEs than using the pretransplant variables only. Proper screening protocol for high-risk recipients may be necessary to reduce the incidence of post-kidney transplantation CVEs. Background: Cardiovascular death is the leading cause of mortality in kidney transplant recipients (KTRs). Although risk factors for post-transplant cardiovascular events (CVEs) have been established, previous studies primarily focused on factors at the time of transplantation without integrating post-transplant factors into the analyses. In addition, most studies were conducted in a mixed population of cyclosporine A and tacrolimus-based immunosuppression, which have different metabolic effects. This study aims to evaluate factors for post-transplant CVEs, including both pretransplant and post-transplant variables, specifically in a population of KTRs receiving tacrolimus-based immunosuppression. Methods: Competing risk regression was performed modeling participant demographics, transplant characteristics, and post-transplant time-updated variables. The primary outcome was the composite of post-transplant CVEs, which included myocardial infarction, heart failure, ischemic stroke, peripheral arterial disease, and cardiovascular death. Results: The incidence of post-transplant CVEs was 15.88 per 1000 patient-years among 553 KTRs included in the study. Key factors significantly associated with post-transplant CVEs included recipient age, diabetes mellitus status, post-transplant hemoglobin A1c, 24-hour urine creatinine clearance, post-transplant serum calcium, and rejection. KTRs with a history of T-cell–mediated rejection or antibody-mediated rejection were at a three-fold (95% confidence interval, 1.22 to 7.37; P value 0.016) and 3.38-fold (95% confidence interval, 1.13 to 10.09; P value 0.029) higher risk for post-transplant CVEs, respectively. Compared with models using pretransplant factors alone, models that included both pretransplant and post-transplant variables demonstrated significantly higher prediction performance. Conclusions: Allograft rejections significantly increased the risk of post-transplant CVEs. Surveillance protocols for post-transplant CVEs should include KTRs with a history of allograft rejection, in addition to the traditional high-risk groups.

27 November 2023 in Clinical Case Reports
Verified
Journal Article
Open access
TWThunyatorn Wuttiputhanun
Thunyatorn Wuttiputhanun
NTNatavudh Townamchai
Natavudh Townamchai
SESomchai Eiam‐Ong
Somchai Eiam‐Ong
KTKullaya Takkavatakarn
Kullaya Takkavatakarn
Key Clinical Message: Managing mixed acid–base disorders can be diagnostically challenging, particularly when metabolic acidosis and metabolic alkalosis occur simultaneously. When dealing with metabolic alkalosis, a comprehensive approach involves taking a detailed medical history, assessing volume status, and performing urine chloride analysis. Routine calculation of the anion gap is important to identify masked wide anion gap metabolic acidosis. We report a case of a 32‐year‐old female with type 1 diabetes mellitus, presented with intractable vomiting for 2 days with hyperglycemia, hypokalemia, and metabolic alkalosis, along with a wide anion gap. She was diagnosed with “diabetic ketoalkalosis” due to diabetic ketoacidosis combined with vomiting‐induced metabolic alkalosis. She became clinically stable after resuscitation with normal saline, intravenous potassium, and intravenous insulin.

1 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TTTheerachai Thammathiwat
Theerachai Thammathiwat
SUSuwasin Udomkarnjananun
Suwasin Udomkarnjananun
TWThunyatorn Wuttiputhanun
Thunyatorn Wuttiputhanun
ABAthiphat Banjongjit
Athiphat Banjongjit
CWChayada Wattanaburanon
Chayada Wattanaburanon
NTNatavudh Townamchai
Natavudh Townamchai
Preformed donor-specific HLA antibodies (DSA) are a major risk factor for antibody-mediated rejection (ABMR) and graft loss after kidney transplantation. While pre-transplant desensitization can reduce DSA levels, the impact of persistent vs. resolved DSA on long-term outcomes remains unclear. This study investigated the association between post-transplant DSA status and clinical outcomes in kidney transplant recipients. This retrospective cohort study investigated the impact of post-transplant DSA persistence on clinical outcomes in kidney transplant recipients at King Chulalongkorn Memorial Hospital between 2009 and 2019. Patients with pre-transplant DSA positivity (detected by Luminex but negative by CDC-AHG) were categorized into ‘resolved’ (DSA < 500 MFI) and ‘persistent’ (DSA > 500 MFI) groups based on post-transplant Luminex results. Outcomes evaluated included biopsy-proven acute rejection (ABMR and TCMR), graft loss, mortality, and post-transplant complications. A total of 50 KTr were enrolled in the study. The median (interquartile range, IQR) DSA level was 1,556 (3,491) MFI for class I and 0 (888) MFI for class II. 57% of patients underwent pre-transplant desensitization. The median follow-up time after transplantation was 5.5 (IQR 3.3) years. The group with persistent DSA (n = 16) exhibited a significant higher rate of ABMR compared to the group with resolved DSA (n = 34) (p = 0.047, log-rank test). Factors associated with persistent DSA included recipient age over 50 and lower tacrolimus levels at six months (less than 7.25 ng/mL). Monitoring DSA levels is crucial in kidney transplant recipients, as persistent DSA is strongly associated with an increased risk of ABMR. Maintaining higher tacrolimus levels at 6 months tends to resolve DSA post-transplant. For patients with persistent DSA, surveillance biopsies should be considered to facilitate early detection and treatment of rejection, thus preserving kidney allograft function.

17 July 2025 in Transplant Infectious Disease
Verified
Journal Article
Closed access
SKSirihatai Konwai
Sirihatai Konwai
STSupawas Thawornkaew
Supawas Thawornkaew
CRChanyanuch Rakpithayanon
Chanyanuch Rakpithayanon
NTNatavudh Townamchai
Natavudh Townamchai
JSJerasit Surintrspanont
Jerasit Surintrspanont
TWThunyatorn Wuttiputhanun
Thunyatorn Wuttiputhanun

26 August 2026 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
PKPattharasai Kachornvitaya
Pattharasai Kachornvitaya
XZXinlei Zhu
Xinlei Zhu
SBSergio Bardaro
Sergio Bardaro
VMValentin Mocanu
Valentin Mocanu
MWMélissa V. Wills
Mélissa V. Wills
Jerry DangJerry Dang
Jerry Dang